The suitability of an in situ perfusion model for permeability determinations: Utility for BCS class I biowaiver requests

Molecular Pharmaceutics

Volumn 3, Issue 6, 2006, Pages 686-694

  Kim, Jae Seung ^a   Mitchell, Stefanie ^a   Kijek, Paul ^a   Tsume, Yasuhiro ^a   Hilfinger, John ^a   Amidon, Gordon L ^a  

^a TSRL INC   (United States)

Author keywords

Bioavailability; Biopharmaceutics Classification System; Confidence interval; In situ rat perfusion; Permeability

Indexed keywords

AMOXICILLIN; ATENOLOL; CAFFEINE; CARBAMAZEPINE; CIMETIDINE; ENALAPRILAT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; KETOPROFEN; MANNITOL; METHYLDOPA; METOPROLOL; NAPROXEN; PHENAZONE; PINDOLOL; PIROXICAM; PROPRANOLOL; RANITIDINE; THEOPHYLLINE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG RESEARCH; DRUG SOLUBILITY; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; JEJUNUM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CACO-2 CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTESTINAL ABSORPTION; MALE; METOPROLOL; MODELS, BIOLOGICAL; MODELS, THEORETICAL; PERFUSION; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE STANDARDS;

EID: 33846130991     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp060042f     Document Type: Article

References (41)

1. Center for Drug Evaluation and Research. Waiver of In Vivo Bioavailabiiity and Bioequivalence Studies for Immediate Release Dosage Forms Containing Certain Active Moieties/Active Ingredients based on a Biopharmaceutics Classification System. FDA: 1999. http://www.fda.gov/cder/ guidance/3618fnl.pdf (accessed August 2005).
2. Sun, D.; Yu, L. X.; Hussain, M. A.; Wall, D. A.; Smith, R. L.; Amidon, G. L. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr. Opin. Drug Discovery Dev. 2004, 7 (1), 75-85.
3. Pelkonen, O.; Boobis, A. R.; Gundert-Remy, U. In vitro prediction of gastrointestinal absorption and bioavailability: an experts' meeting report. Eur. J. Clin. Pharmacol. 2001, 57 (9), 621-9.
4. Lennernas, H.; Lee, I. D.; Fagerholm, U.; Amidon, G. L. A residence-time distribution analysis of the hydrodynamics within the intestine in man during a regional single-pass perfusion with Loc-I- Gut: in-vivo permeability estimation. J. Pharm. Pharmacol. 1997, 49 (7), 682-6.
5. Tamura, S.; Tokunaga, Y.; Ibuki, R.; Amidon, G. L.; Sezaki, H.; Yamashita, S., The site-specific transport and metabolism of tacrolimus in rat small intestine. J. Pharm. Exp. Ther. 2003, 306 (1), 310-6.
6. Han, H.; de Vrueh, R. L.; Rhie, J. K.; Covitz, K. M.; Smith, P. L.; Lee, C. P.; Oh, D. M.; Sadee, W.; Amidon, G. L. 5′-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm. Res. 1998, 15 (8), 1154-9.
7. Walter, E.; Janich, S.; Roessler, B. J.; Hilfinger, J. M.; Amidon, G. L. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J. Pharm. Sci. 1996, 85 (10), 1070-6.
8. Hidalgo, I.; Raub, T.; Borchardt, R., Characterization of the Human Colon Carcinoma Cell Line (Caco-2) as a Model System for Intestinal Epithelial Permeability. Gastroenterology 1989, 96, 736-49.
9. Artursson, P.; Karlsson, J., Correlation Between Oral Drug Absorption In Humans And Apparent Drug Permeability Coefficients In Human Intestinal Epithelial (CaCo-2) Cells. Biochem. Biophys. Res. Commun. 1991, 175 (3), 880-5.
10. Regardh, C. G.; Borg, K. O.; Johansson, R.; Johnsson, G.; Palmer, L. PK studies on the selective betal-receptor antagonist metoprolol in man. J. Pharmacokinet. Biopharm. 1974, 2, (4), 347-64.
11. Center for Drug Evaluation and Research. Approved Drug Products with Therapeutic Equivalence Evaluations. FDA: 2006. http://www.fda.gov/cder/orange/ defaulLhtm (accessed August 2005).
12. Siersma, C.; Kim, J.; Clark, L.; Walton, J.; Amidon, G. Evaluation of a Rank Order of the Permeability Ratios of Various Compounds for Categorization into the Biopharmaceutics Classification System. Pharm. Res. 1999, 15 (Suppl.), AAPS Meeting Abstract.
13. Lipka, E.; Lennernas, H.; Amidon, G. L. Interspecies correlation of permeability estimates: The feasibility of animal data for predicting oral absorption in humans. Pharm. Res. 1995, 12, S-311.
14. Amidon, G. L.; Sinko, P. J.; Fleisher, D. Estimating human oral fraction dose absorbed: A correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res. 1988, 5 (10), 651-4.
15. Avdeef, A.; Berger, C. M.; Brownell, C. pH-metric solubility. 2: correlation between the acid-base titration and the saturation shake-flask solubility-pH methods. Pharm. Res. 2000, 17 (1), 85-9.
16. Avdeef, A.; Berger, C. M. pH-metric solubility. 3. Dissolution titration template method for solubility determination. Eur. J. Pharm. Sci. 2001, 14 (4), 281-91.
17. Physicians' Desk Reference, 59th ed.; Medical Economics Company: Montvale, NJ, 2005.
18. Fagerholm, U.; Johansson, M.; Lennernas, H. Comparison Between Permeability Coefficients in Rat and Human Jejunum. Pharm. Res. 1996, 13 (9), 1336-42.
19. Winiwarter, S.; Bonham, N. M.; Ax, F.; Hallberg, A.; Lennernas, H.; Karlen, A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 1998, 41 (25), 4939-49.
20. Takamatsu, N.; Welage, L. S.; Idkaidek, N. M.; Liu, D. Y.; Lee, P. I.; Hayashi, Y.; Rhie, J. K.; Lennernas, H.; Barnett, J. L.; Shah, V. P.; Lesko, L.; Amidon, G. L. Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm. Res. 1997, 14 (9), 1127-32.
21. Takamatsu, N.; Kim, O. N.; Welage, L. S.; Idkaidek, N. M.; Hayashi, Y.; Barnett, J.; Yamamoto, R.; Lipka, E.; Lennernas, H.; Hussain, A.; Lesko, L.; Amidon, G. L. Human jejunal permeability of two polar drugs: cimetidine and ranitidine. Pharm. Res. 2001, 18 (6), 742-4.
22. Lennernas, H.; Knutson, L.; Knutson, T.; Hussain, A.; Lesko, L.; Salmonson, T.; Amidon, G. L. The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique. Eur. J. Pharm. Sci. 2002, 15 (3), 271-7.
23. Kasim, N. A.; Whitehouse, M.; Ramachandran, C.; Bermejo, M.; Lennernas, H.; Hussain, A. S.; Junginger, H. E.; Stavchansky, S. A.; Midha, K. K.; Shah, V. P.; Amidon, G. L. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharm. 2004, 1 (1), 85-96.
24. Lennernas, H.; Ahrenstedt, O.; Hallgren, R.; Knutson, L.; Ryde, M.; Paalzow, L. K. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 1992, 9 (10), 1243-51.
25. Lennernas, H.; Knutson, L.; Knutson, T.; Lesko, L.; Salmonson, T.; Amidon, G. L. Human effective permeability data for furosemide, hydrochlothiazide, ketoprofen and naproxen to be used in the proposed biopharmaceutical classification for IR products. Pharm. Res. 1995, 12 (Suppl.), S-396.
26. Lindahl, A.; Sandstrom, R.; Ungell, A. L.; Knutson, L.; Abrahamsson, B.; Lennernas, H. A human study of the regional jejunal effective permeability of fluvastatin, atenolol, metoprolol and antipyrine. Pharm. Res. 1995, 12 (Suppl.), S-295.
27. Koljonen, M.; Hakala, K. S.; Ahtola-Satila, T.; Laitinen, L.; Kostiainen, R.; Kotiaho, T.; Kaukonen, A. M.; Hirvonen, J. Evaluation of cocktail approach to standardise Caco-2 permeability experiments. Eur. J. Pharm. Biopharm. 2006, Jun 30 (E-pub ahead of print).
28. Bourdet, D. L.; Pollack, G. M.; Thakker, D. R. Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells. Pharm. Res. 2006, 23 (6), 1178-87.
29. Paintaud, G.; Alvan, G.; Dahl, M. L.; Grahnen, A.; Sjovall, J.; Svensson, J. O. Nonlinearity of amoxicillin absorption kinetics in human. Eur. J. Clin. Pharmacol. 1992, 43 (3), 283-8.
30. Magee, D. F.; Dalley, A. F. I. Digestion and the Structure and Function of the Gut. S. Karger Publishers, Inc.: Basel, Switzerland, 1986; Vol. 8.
31. Center for Drug Evaluation and Research. Statistical Approaches to Establishing Bioequivalence; Guidance for Industry; FDA: 2001. http://www.fda.gov/cder/guidance/3616fnl.htm (accessed September 2005).
32. Center for Drug Evaluation and Research. Cholestyramine powder in vitro Bioequivalence; Guidance for Industry, Interim; FDA: 1993. http://www.fda.gov/cder/guidance/cholesty.pdf (accessed October 2005).
33. Amidon, G.; Lennernas, H.; Shah, V.; Crison, J. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12, 413-20.
34. Lennernas, H.; Ahrenstedt, O.; Ungell, A. L. Intestinal drug absorption during induced net water absorption in man; a mechanistic study using antipyrine, atenolol and enalaprilat. Br. J. Clin. Pharmacol. 1994, 37 (6), 589-96.
35. Lennernas, H.; Nylander, S.; Ungell, A. L. Jejunal permeability: a comparison between the ussing chamber technique and the single-pass perfusion in humans. Pharm. Res. 1997, 14 (5), 667-71.
36. Sun, D.; Lennernas, H.; Welage, L. S.; Barnett, J. L.; Landowski, C. P.; Foster, D.; Fleisher, D.; Lee, K. D.; Amidon, G. L. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 2002, 19 (10), 1400-16.
37. Yu, L. X.; Amidon, G. L.; Polli, J. E.; Zhao, H.; Mehta, M. U.; Conner, D. P.; Shah, V. P.; Lesko, L. J.; Chen, M. L.; Lee, V. H.; Hussain, A. S. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 2002, 19 (7), 921-5.
38. Polli, J. E.; Yu, L. X.; Cook, J. A.; Amidon, G. L.; Borchardt, R. T.; Burnside, B. A.; Burton, P. S.; Chen, M. L.; Conner, D. P.; Faustino, P. J.; Hawi, A. A.; Hussain, A. S.; Joshi, H. N.; Kwei, G.; Lee, V. H.; Lesko, L. J.; Lipper, R. A.; Loper, A. E.; Nerurkar, S. G.; Polli, J. W.; Sanvordeker, D. R.; Taneja, R.; Uppoor, R. S.; Vattikonda, C. S.; Wilding, I.; Zhang, G. Summary workshop report: biopharmaceutics classification system-implementation challenges and extension opportunities. J. Pharm. Sci. 2004, 93 (6), 1375-81.
39. Blume, H. H.; Schug, B. S. The biopharmaceutics classification system (BCS): class III drugs-better candidates for BA/BE waiver? Eur. J. Pharm. Sci. 1999, 9 (2), 117-21.
40. Dressman, J.; Butler, J.; Hempenstall, J.; Reppas, C. The BCS: Where do we go from here? Pharm. Technol. 2001, 7, 69-76.
41. Kanfer, I., Report on the International Workshop on the Biopharmaceutics Classification System (BCS): scientific and regulatory aspects in practice. J. Pharm. Pharm. Sci. 2002, 5(1), 1-4.